Where can I find Pfizer's full financial statements for 2012?

The full consolidated financial statements, notes, and the independent auditor's report for the period ending December 30, 2012, are incorporated by reference from Pfizer's 2012 Financial Report and its 2012 Form 10-K. This filing (10-K/A) primarily lists these incorporated documents and other exhibits.

What is the significance of the 'Exhibits' section in this filing?

The Exhibits section lists all the supporting documents filed with the SEC. For investors, these include critical governance documents (like the Certificate of Incorporation and By-laws), details of debt obligations (indentures), and information on various management and employee compensation plans. These provide context to the company's structure, financial commitments, and incentive programs.

Why are financial statement schedules omitted?

Financial statement schedules are omitted because they are either not required by SEC regulations for a company of Pfizer's size and structure, or the information they would contain is already presented within the main financial statements or their accompanying notes.

Does this amendment change Pfizer's reported financial performance for 2012?

This filing is an amendment to the original 10-K and primarily serves to list exhibits and incorporate previously reported financial information. It does not typically introduce new or revised financial performance data unless explicitly stated as an amendment to specific financial statement items, which is not indicated here. The financial performance for 2012 should be reviewed in the original 2012 10-K and accompanying financial statements.

PFE 10-K FY2012 Annual Report — Revenue, Net Income, EPS

Summary

This filing for Pfizer Inc. (PFE) as of December 30, 2012, is primarily an amendment to its 2012 Form 10-K. It details the exhibits filed alongside the financial statements, which are incorporated by reference from Pfizer's 2012 Financial Report. Investors should note that this document itself does not contain the full financial statements or performance data but rather serves as a comprehensive list and reference to these critical components. The filing includes various corporate governance documents, debt indentures, and management/employee compensation plans, reflecting the company's established structure and ongoing operational framework at the close of the 2012 fiscal year. Key information for investors lies in understanding that the substantive financial details and management's discussion and analysis would be found in the incorporated 2012 10-K Report and the referenced 2012 Financial Report. This amendment focuses on the supplementary materials that underpin the financial reporting, including legal and compensatory agreements. For a complete picture, investors must refer to the full financial statements and related disclosures mentioned within this filing.

Financial Highlights

56 data points

Beta

Revenue

$54.66B

0.8% Gross Margin

Net Income

$14.57B

0.3% Net Margin

EPS (Diluted)

$1.94

Total Assets

$185.80B

Cash & Equivalents

$10.08B

Free Cash Flow

$15.42B

Financial Statements

Beta

Revenue	$54.66B
Cost of Revenue	$9.82B
Gross Profit	$44.84B
SG&A Expenses	$15.17B
Operating Income	$8.99B
Interest Expense	$1.52B
Net Income	$14.57B
EPS (Basic)	$1.96
EPS (Diluted)	$1.94
Shares Outstanding (Basic)	7.44B
Shares Outstanding (Diluted)	7.51B

Key Highlights

1This filing is an amendment (10-K/A) to Pfizer Inc.'s 2012 Annual Report (10-K), filed on February 28, 2013, for the period ending December 30, 2012.
2The core of the filing (Item 15) lists and incorporates by reference the company's consolidated financial statements, notes, and independent auditor's report from its 2012 Financial Report.
3A comprehensive list of exhibits is provided, including significant corporate documents like the Restated Certificate of Incorporation and By-laws.
4Details of various debt indentures, including those from legacy Wyeth, are incorporated by reference, outlining the terms and rights associated with long-term debt.
5Numerous management contracts, compensatory plans, and stock plans (e.g., 2001 Stock and Incentive Plan, Pfizer Inc. 2004 Stock Plan, Wyeth plans) are listed, reflecting executive and employee compensation structures.
6The filing includes the consent of KPMG LLP as the independent registered public accounting firm.
7Financial statement schedules are omitted as they are not required or information is provided elsewhere, simplifying the filing structure.

PFIZER INC Annual Report (Amendment), Year Ended Dec 31, 2012

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions